Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Golidocitinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Golidocitinib Green Lit by China’s NMPA for Relapsed/Refractory PTCL
    Golidocitinib Green Lit by China’s NMPA for Relapsed/Refractory PTCL

    20 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/golidocitinib-approved-in-china-as-first-in-class-jak1-only-inhibitor-for-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma-302176781.html

    PR NEWSWIRE
    20 Jun 2024
    Share Share
    Dizal's Golidocitinib Trial Demonstrates Durable Benefits for r/r PTCL
    Dizal's Golidocitinib Trial Demonstrates Durable Benefits for r/r PTCL

    10 Dec 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/dizals-golidocitinib-pivotal-trial-demonstrates-superior-and-durable-clinical-benefits-for-patients-with-rr-ptcl-in-oral-presentation-at-2023-ash-302010729.html

    PR NEWSWIRE
    10 Dec 2023
    Share Share
    Golidocitinib Granted Priority Review by NMPA for the Treatment of r/r PTCL
    Golidocitinib Granted Priority Review by NMPA for the Treatment of r/r PTCL

    21 Sep 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/golidocitinib-granted-priority-review-by-china-nmpa-for-the-treatment-of-rr-ptcl-301934854.html

    PR NEWSWIRE
    21 Sep 2023
    Share Share
    Dizal Announces China CDE Acceptance of New Drug Application for Golidocitinib
    Dizal Announces China CDE Acceptance of New Drug Application for Golidocitinib

    14 Sep 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/dizal-announces-china-cde-acceptance-of-new-drug-application-for-golidocitinib-for-relapsed-or-refractory-ptcl-301927562.html

    PR NEWSWIRE
    14 Sep 2023
    Share Share